Rapid Communication
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4096-4099
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4096
Table 1 Baseline characteristics of the patients
PatientSexAge(yr)LiverbiopsyComplica-tionsHBV DNA(pg/mL )1LAM3(wk)YMDD
1F77CirrhosisHCC896M204I
2M40CAH Ishak 9;22156M204V
3M63CirrhosisUndetectable2188M204V
4F68CirrhosisF2 esoph varices160044M204I
5M55CirrhosisUndetectable2104M204V, L180M
6F58Cirrhosis45088WT
7M68CirrhosisF2 esoph varices6476WT
8M57CAH Ishak 7; 4162116WT
9M65Cirrhosis7888WT
10M58Cirrhosis0.252WT
11F75Cirrhosis3.100116WT
Table 2 Results of treatment with tenofovir disoproxil fumarate (TDF) in the individual patients
Patient(YMDD/WT)BasalHBVDNA1(cp/mL)Durationoftreatmentwith TDF(wk)HBVDNA(end ofTDF)( cp/mL)Drugsubstituted for TDFHBV DNAaftersubstitutionof TDF
1 (YMDD)1000-200096< 1000ADV130.000 cp/mL
2 (YMDD)4.8 × 106144< 1000ADVNo viral
rebound
3 (YMDD)1000-200056< 1000LAMNo viral
rebound
4 (YMDD)1000-200080< 10002ADV + LAMNo viral
rebound
5 (YMDD)1000-200060< 1000ADVNo viral
rebound
6 WT< 1000108< 1000ADVNo viral
rebound
7 WT< 100076< 1000ADV21 000 cp/mL
8 WT< 100088< 1000ADV2700 cp/mL
9 WT< 1000116< 1000ADVNo viral
rebound
10 WT< 100052< 1000LAM added toNo viral
TDFrebound
11 WT< 100024< 1000LAMNo viral
rebound